Literature DB >> 8369378

Epidemiologic assessment of risks of adverse reactions associated with intermittent exposure.

U Feldmann1.   

Abstract

Measures of risk of adverse reactions, such as the absolute risk, the relative risk, and the excess risk, are analyzed for individuals who are exposed occasionally for periods of varying duration. This type of exposure is of particular importance for the epidemiologic assessment of drug safety. A Poisson point process model that allows for the simultaneous consideration of concomitant factors is derived for the estimation of the hazard rates. The model can judge acute adverse reactions and is applicable not only for rare risks since an undesired effect may occur repeatedly for an individual. Hazard estimation is achieved with the aid of the maximum likelihood method for several sampling designs, such as cohort studies, case-cohort studies, and case studies. In the latter design only those individuals who have had an adverse reaction during the time of observation are considered for hazard estimation. An application to the analysis of wound-healing impairments is given.

Mesh:

Year:  1993        PMID: 8369378

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

Review 1.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.

Authors:  L Degenhardt; W Hall; M Warner-Smith
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

Review 2.  Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis.

Authors:  Issa J Dahabreh; Jessica K Paulus
Journal:  JAMA       Date:  2011-03-23       Impact factor: 56.272

3.  Case-crossover design and its implementation in R.

Authors:  Zhongheng Zhang
Journal:  Ann Transl Med       Date:  2016-09

4.  Analysis of Observational Self-matched Data to Examine Acute Triggers of Outcome Events with Abrupt Onset.

Authors:  Elizabeth Mostofsky; Brent A Coull; Murray A Mittleman
Journal:  Epidemiology       Date:  2018-11       Impact factor: 4.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.